Diagnostic value of combined 18F-FDG PET/MRI for staging and restaging in paediatric oncology

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 11, 2012, Pages 1745-1755

  Pfluger, Thomas ^a   Melzer, Henriette I ^a   Mueller, Wolfgang P ^a   Coppenrath, Eva ^a   Bartenstein, Peter ^a   Albert, Michael H ^a   Schmid, Irene ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

18F FDG PET; Combined registered image analysis; MRI; Paediatric oncology

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE MEGLUMINE;

ADOLESCENT; ADULT; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER RESTAGING; CANCER STAGING; CHILD; CHILDHOOD CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; INFANT; INFLAMMATORY DISEASE; INTERMETHOD COMPARISON; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SOLID TUMOR;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84868208874     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2228-3     Document Type: Article

References (40)

1. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 2010;28:2625-34.
2. Schiepers C, Dahlbom M. Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging. Eur Radiol 2011;21:548-54.
3. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79.
4. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508.
5. Zaidi H, Del Guerra A. An outlook on future design of hybrid PET/MRI systems. Med Phys 2011;38:5667-89.
6. Kleis M, Daldrup-Link H, Matthay K, Goldsby R, Lu Y, Schuster T, et al. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging 2009;36:23-36.
7. London K, Cross S, Onikul E, Dalla-Pozza L, Howman-Giles R. 18F-FDG PET/CT in paediatric lymphoma: comparison with conventional imaging. Eur J Nucl Med Mol Imaging 2011;38:274-84.
8. Mawlawi O, Townsend DW. Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging 2009;36 Suppl 1:S15-29.
9. Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dualmodality 18F-FDG PET/CT examinations. J Nucl Med 2005;46:608-13.
10. Kleinerman RA. Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr Radiol 2006;36 Suppl 2:121-5.
11. Pichler BJ, Kolb A, Nägele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010;51:333-6.
12. Darge K, Jaramillo D, Siegel MJ. Whole-body MRI in children: current status and future applications. Eur J Radiol 2008;68:289- 98.
13. Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290:3199-206.
14. von Schulthess GK, Schlemmer HP. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 2009;36 Suppl 1: S3-9.
15. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med 2008;14:459-65.
16. Eiber M, Martinez-Möller A, Souvatzoglou M, Holzapfel K, Pickhard A, Löffelbein D, et al. Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging 2011;38:1691-701.
17. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 2010;51:1198-205.
18. Stauss J, Franzius C, Pfluger T, Juergens KU, Biassoni L, Begent J, et al. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. Eur J Nucl Med Mol Imaging 2008;35:1581-8.
19. Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun 2004;25:651-6.
20. Wegner EA, Barrington SF, Kingston JE, Robinson RO, Ferner RE, Taj M, et al. The impact of PET scanning on management of paediatric oncology patients. Eur J Nucl Med Mol Imaging 2005;32:23-30.
21. Goethals I, Hoste P, De Vriendt C, Smeets P, Verlooy J, Ham H. Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma. Eur J Nucl Med Mol Imaging 2010;37:462-7.
22. Przkora R, Perez-Canto A, Ertel W, Heyde CE. Ganglioneuroma: primary tumor or maturation of a suspected neuroblastoma? Eur Spine J 2006;15:363-5.
23. Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, et al. The role of quantitative 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002;43:510-8.
24. Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001;219:774- 7.
25. Kumar R, Halanaik D, Malhotra A. Clinical applications of positron emission tomography-computed tomography in oncology. Indian J Cancer 2010;47:100-19.
26. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61-77.
27. Weisdorf DJ, Craddock PR, Jacob HS. Glycogenolysis versus glucose transport in human granulocytes: differential activation in phagocytosis and chemotaxis. Blood 1982;60:888-93.
28. Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, et al. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002;29:1155-65.
29. London K, Stege C, Cross S, Onikul E, Graf N, Kaspers G, et al. 18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors. Pediatr Radiol 2012;42:418-30.
30. Ratib O, Beyer T. Whole-body hybrid PET/MRI: ready for clinical use? Eur J Nucl Med Mol Imaging 2011;38:992-5.
31. Hoffer FA. Magnetic resonance imaging of abdominal masses in the pediatric patient. Semin Ultrasound CT MR 2005;26:212-23.
32. Foster K, Chapman S, Johnson K. MRI of the marrow in the paediatric skeleton. Clin Radiol 2004;59:651-73.
33. Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H. Impact of FDG-PET/CT in the management of lymphoma. Ann Nucl Med 2011;25:701-16.
34. Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jürgens H, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR AmJ Roentgenol 2001;177:229-36.
35. Mody RJ, Bui C, Hutchinson RJ, Yanik GA, Castle VP, Frey KA, et al. FDG PET imaging of childhood sarcomas. Pediatr Blood Cancer 2010;54:222-7.
36. Franzius C, Juergens KU. PET/CT in paediatric oncology: indications and pitfalls. Pediatr Radiol 2009;39 Suppl 3:446-9.
37. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
38. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 1-646.
39. Depas G, De Barsy C, Jerusalem G, Hoyoux C, Dresse MF, Fassotte MF, et al. 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 2005;32:31-8.
40. Loeffelbein DJ, Souvatzoglou M, Wankerl V, Martinez-Möller A, Dinges J, Schwaiger M, et al. PET-MRI fusion in head-and-neck oncology: current status and implications for hybrid PET/MRI. J Oral Maxillofac Surg 2012;70:473-83.